HIV Mutation Detail Information

> Q148H Search Result


Mutation Information
Mutation Site Q148H
Mutation Type Amino acid level
Gene/Protein/Region Type IN
Combined Mutation in.Q148H+in.G140S
Relevant Drug raltegravir (RAL);elvitegravir (EVG)
Literature Information
PubMed PMID 32389483
Published Year 2020
Journal Bioorganic & medicinal chemistry
Title Design, synthesis and SAR study of bridged tricyclic pyrimidinone carboxamides as HIV-1 integrase inhibitors.
Author Patel M,Naidu BN,Dicker I,Higley H,Lin Z,Terry B,Protack T,Krystal M,Jenkins S,Parker D,Panja C,Rampulla R,Mathur A,Meanwell NA,Walker MA
Evidence The [3.2.2]-bridged tricyclic system was identified as an advantageous chemotype, with representatives exhibiting excellent antiviral activity against both wild-type viruses and the G140S/Q148H resistant virus that arises in response to therapy with raltegravir and elvitegravir.

Contents
Description
Mutation Information Note
  • Gene/Protein/Region Type: Virus Gene (e.g. LMP-1) or Virus Protein (e.g. Rep 68) or Virus Region (e.g. S, X)
Literature Information Note
  • Evidence: sentence contains this mutation information in the citation